article thumbnail

Pathbreakers: The journey of first generics

Pharmaceutical Technology

Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. These medicines comprise about 10% of all generics approved each year.

article thumbnail

Generic Drugs Approved but not Launched – How to Tell When Generic Drugs Will hit the Market

Drug Patent Watch

Just because a drug has received FDA approval does not mean that it is available in the marketplace. The post Generic Drugs Approved but not Launched – How to Tell When Generic Drugs Will hit the Market appeared first on DrugPatentWatch - Make Better Decisions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Indian pharma manufacturing: rising investment in Andhra Pradesh

Pharmaceutical Technology

Indian pharma manufacturing continues to be the backbone of drug supplies worldwide, and GlobalData analysis suggests US overreliance on the country for generic drug supply. Most sites in Andhra Pradesh and Telangana had FDA and/or EMA approval (297 out of a total 476 sites).

article thumbnail

Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth

Pharmaceutical Technology

increase in revenue from 2020 to 2021 from sales of Revlimid, its multiple myeloma therapy, with a global analyst consensus sales forecast of $12.8bn for 2021, according to GlobalData’s Drugs Database. However, other challenges facing biopharmaceutical companies include growing generic drug competition, which places pressure on drug prices.

article thumbnail

Faster FDA Approvals Don’t Affect Generic Drug Availability or Cost

Pharmacy Checkers

I’m proud to share that PharmacyChecker has published a white paper that examines prices and availability of newly approved generic drugs. Out of 40 generic medications that were approved from 2017 to 2018, PharmacyChecker research found the following: 42.5% (17) are not available in the U.S. generic versions.

article thumbnail

Market cap downturn hits over half of top 20 biopharmaceutical companies in Q1 2023

Pharmaceutical Technology

over Q1 2023, attributed to a surge in sales of their jointly developed drug Dupixent, which recently gained approval for the treatment of paediatric atopic dermatitis, eosinophilic oesophagitis and prurigo nodularis. Sanofi and Regeneron’s market capitalisation grew by 12.4%

article thumbnail

After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi

pharmaphorum

The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly genericised market. The post After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi appeared first on.